Insulin Glargine

Efesa, is a long-acting Erythropoietin indicated for CKD-induced anemia in dialysis and non-dialysis patients. Efesa is a hybrid Fc of IgG4 and IgD that provides hinge flexibility and long serum half-life without causing toxicity to target cells. Global Phase 3 trial for non-dialysis indication is currentl...

Nimotuzumab binds with intermediate affinity and high specificity to the extracellular domain of EGFR and blocks the binding of the EGF to its receptor and inhibits tumor cell growth. The molecule induces cell lysis through ADCC mechanism. Nimotuzumab provides vaccinal effect that induce memory T-cell ...

Indication: Chronic kidney diseases induced anemia (dialysis and non-dialysis)

Bevacizumab acts by selectively binding circulating VEGF, thereby inhibiting the binding of VEGF to its cell surface receptors. This inhibition leads to a reduction in microvascular growth of tumor blood vessels that limits the blood supply to tumor tissues.The indication is for Colorectal Cancer...

PT Kalbe Farma Tbk through its subsidiary PT Kalbe Genexine Biologicswith Shangai Henlius Biotech, Inc have entered into an exclusive license agreement for the development and commercialization of serplulimab injection in 12 Middle East and North African countries including Saudi Arabia, the United Arab Emirates, etc.